Immuron Ltd — Capital/Financing Update 2012

May 9, 2012

ABN: 80 063 114 045 Level 1, 39 Leveson Street North Melbourne, Vic 3051 Tel: +61 3 8637 1107 Fax: +61 3 9328 1675 www.immuron.com

==> picture [193 x 41] intentionally omitted <==

IMMURON AGREEMENT TO SELL TRAVELAN IN THAILAND, HONG KONG, CAMBODIA, VIETNAM & LAOS

• Agreement with specialist distributor

• Regulatory submission to commence immediately

• First sales of Travelan in five SE Asian markets

10 May 2012, Melbourne, Australia : Australian biopharmaceutical company Immuron Limited (ASX: IMC), manufacturer of Travelan®, has entered into an agreement with IntegraMed Asia (Thailand) Co Ltd for the sale of Travelan in Thailand, Hong Kong, Cambodia, Vietnam and Laos.

Travelan is clinically‐proven to prevent with 90% efficacy the main cause of travellers’ diarrhoea. Travellers’ diarrhoea is endemic in each of these countries, which according to the World Tourism Organization, hosted in excess of an aggregate of 44 million travellers in 2010. This is in addition to the local resident population of approximately 190 million people.

Under the agreement IntegraMed Asia is required to attain regulatory approval for the sale of Travelan in its licensed countries and to sell specified minimum volumes. The regulatory approval process has already commenced. There is also an agreed timetable for the launch and sales of Travelan in the licensed countries.

IntegraMed Asia is a licensed seller in the Indo‐China market with branches in Bangkok, Singapore and the United Kingdom. Founded in 1999, it manages health product registration, distribution and sales.

“Thailand and the other countries licensed to IntegraMed are very relevant to Travelan, especially because the large flux of tourists visiting and/or passing through these countries. Based on our current pipeline of transactions, our agreement with IntegraMed is another step in Immuron’s strategy of rolling out Travelan on a global basis to build sales,” said Joe Baini, Immuron’s Chief Executive Officer.

“IntegraMed has specialist knowledge and goodwill in these territories that are imperative in establishing and building sales for Travelan.”

IntegraMed Asia Managing Director, Dr Richard Lu said: “We are enthusiastic about selling Travelan in our licensed countries given its high efficacy in preventing travellers’ diarrhoea in a region where the condition is prevalent. We are impressed with its efficacy in preventing travellers’ diarrhoea, an often debilitating condition and one that has ruined many business and vacation plans.”

Contact

Joe Baini – Chief Executive Officer Rudi Michelson +61 3 8637 1107 Monsoon Communications +61 3 9620 3333 +61 411 402 737

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy‐derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre‐clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).

About IntegraMed Asia

IntegraMed Asia is a boutique healthcare service provider whose mission it is to enable its clients to develop and enhance their business to and from Asia. IntegraMed Asia offers registration and product representation and product sourcing solutions, consulting services, market evaluations and concrete answers for local production plans.